e-learning
resources
London 2016
Sunday, 04.09.2016
Clinical update on bronchiectasis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long term prognosis of non-cystic fibrosis bronchiectasis
Jacinto Hernandez Borge (Badajoz, Spain), Amparo Sanz Cabrera, Jacinto Hernandez Borge, Maria del Carmen Garcia Garcia, Maria Jose Antona Rodriguez, Isabel Asschert Aguero, Pedro Pires Goncalvez, Estefanía Molina Ortiz, Ana Castañar Jover, Francisca Lourdes Marquez Perez
Source:
International Congress 2016 – Clinical update on bronchiectasis
Session:
Clinical update on bronchiectasis
Session type:
Oral Presentation
Number:
276
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jacinto Hernandez Borge (Badajoz, Spain), Amparo Sanz Cabrera, Jacinto Hernandez Borge, Maria del Carmen Garcia Garcia, Maria Jose Antona Rodriguez, Isabel Asschert Aguero, Pedro Pires Goncalvez, Estefanía Molina Ortiz, Ana Castañar Jover, Francisca Lourdes Marquez Perez. Long term prognosis of non-cystic fibrosis bronchiectasis. Eur Respir J 2016; 48: Suppl. 60, 276
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials
A 62-year-old man with scanty mucoid sputum
Related content which might interest you:
Predictors of lung function decline in stable non-cystic fibrosis bronchiectasis
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014
Clinical phenotypes in non-cystic fibrosis bronchiectasis (NCFBE)
Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections
Year: 2014
Retrospective cohort study of adult cystic fibrosis patients colonised with achromobacter Xylosoxidans
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
Positive microbiology findings in non-cystic fibrosis bronchiectasis and co-morbidities
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016
Exacerbations in non-cystic fibrosis bronchiectasis
Source: International Congress 2014 – Healthcare, prevention and adjunctive treatments in respiratory infections
Year: 2014
Is etiology of non-cystic fibrosis bronchiectasis (NCFBE) a risk factor for severe exacerbation?
Source: International Congress 2014 – Healthcare, prevention and adjunctive treatments in respiratory infections
Year: 2014
DLCO predicts disease severity and mortality in patients with non-cystic fibrosis bronchiectasis
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
Persistence of candida dubliniensis in the lower airways of cystic fibrosis patients
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015
A ten year experience of non-cystic fibrosis bronchiectasis from a single center
Source: International Congress 2016 – Asthma, bronchiectasis, and the risk factors for respiratory morbidity
Year: 2016
Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014
Characteristic of a subgroup of non cystic fibrosis bronchiectasis with concomitant asthma
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Etiology and clinical outcome of pediatric non-cystic fibrosis bronchiectasis
Source: Annual Congress 2010 - Paediatric epidemiology: infection, prematurity and congenital abnormalities
Year: 2010
Understanding patients’ experience of living with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Aspects of physiotherapy in various clinical conditions and settings
Year: 2013
Prolonged antibiotics for non-cystic fibrosis purulent bronchiectasis in children and adults: A Cochrane review
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Bacterial colonisation in children with non-cystic fibrosis bronchiectasis: a retrospective longitudinal study
Source: International Congress 2017 – Paediatric bronchology in clinical practice
Year: 2017
International validation of FACED score in 672 patients with non-cystic fibrosis bronchiectasis
Source: International Congress 2016 – Clinical update on bronchiectasis
Year: 2016
Diagnosis and management of non-cystic fibrosis bronchiectasis in children
Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment
Year: 2018
Tuberculosis in patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Comparative analysis of the predictive utility of clinical disease severity scores for non-cystic fibrosis bronchiectasis
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept